



IMUGENE LIMITED

Advanced Vaccine Technologies
Disease control in pigs and poultry

Annual General Meeting
27 November 2009



Today's meeting

- **10.30am**
 - **Address from Chairman - Mr Graham Dowland**
 - **Presentation from CEO - Dr Warwick Lamb**
 - **Your questions**
- **11.00 am**
 - **Formal agenda**
 - **Resolutions**
 - **Meeting close**



This document has been prepared by Imugene Limited (“Imugene”) in connection with providing an overview to interested analysts and investors.

This presentation is being provided for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business activities of Imugene. This presentation is thus by its nature limited in scope and is not intended to provide all available information regarding Imugene. This presentation is not intended as an offer, invitation, solicitation, or recommendation with respect to the purchase or sale of any securities. This presentation should not be relied upon as a representation of any matter that a potential investor should consider in evaluating Imugene.

Imugene and its affiliates, subsidiaries, directors, agents, officers, advisers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained in this presentation, and they do not accept any liability or responsibility for any statement made in, or omitted from, this presentation. Imugene accepts no obligation to correct or update anything in this presentation.

No responsibility or liability is accepted and any and all responsibility and liability is expressly disclaimed by Imugene and its affiliates, subsidiaries, directors, agents, officers, advisers and employees for any errors, misstatements, misrepresentations in or omissions from this presentation.

Any statements, estimates, forecasts or projections with respect to the future performance of Imugene and/or its subsidiaries contained in this presentation are based on subjective assumptions made by Imugene’s management and about circumstances and events that have not yet taken place. Such statements, estimates, forecasts and projections involve significant elements of subjective judgement and analysis which, whilst reasonably formulated, cannot be guaranteed to occur. Accordingly, no representations are made by Imugene or its affiliates, subsidiaries, directors, officers, agents, advisers or employees as to the accuracy of such information; such statements, estimates, forecasts and projections should not be relied upon as indicative of future value or as a guarantee of value or future results; and there can be no assurance that the projected results will be achieved.

Prospective investors should make their own independent evaluation of an investment in Imugene.

Nothing in this presentation should be construed as financial product advice, whether personal or general, for the purposes of section 766B of the Corporations Act 2001 (Cth). This presentation consists purely of factual information and does not involve or imply a recommendation or a statement of opinion in respect of whether to buy, sell or hold a financial product. This presentation does not take into account the objectives, financial situation or needs of any person, and independent personal advice should be obtained. This presentation and its contents have been made available in confidence and may not be reproduced or disclosed to third parties or made public in any way without the express written permission of Imugene.



Chairman's Address

Mr Graham Dowland

Chairman





CEO Presentation

Dr Warwick Lamb
Managing Director



Year in Review

Strategic Alliance with Merial

Signed on 31 December 2008

Year 1 focus: technology transfer & evaluation of manufacturing options

Sublicensed vaccines: PRRS & PPE

Imugene

- Technology transfer
- Provide vaccines for trials
- Expand product pipeline
- Construct new vaccines
- Manage patent position
- Modify existing vaccines if required

Merial

- Fund product development
- Design & perform all trials
- Develop commercial scale manufacturing process
- All regulatory work
- Maximise product range from both platforms

A diverse and deep product portfolio

Stage	Pigs	Poultry
Passed commercial proof of concept	<ul style="list-style-type: none">• PRRS – Porcine Reproductive & Respiratory Syndrome vaccine• Classical Swine Fever vaccine	<ul style="list-style-type: none">• PPE - Poultry Productivity Enhancer proven to boost growth and weight• H5N1 avian influenza vaccine• Coccidiosis preventative vaccine
Passed laboratory testing	<ul style="list-style-type: none">• Swine influenza vaccines for H1N1 and H3N2 strains	<ul style="list-style-type: none">• H7 and H9 avian influenza vaccine• Chicken Anaemia Virus• Infectious Bursal Disease vaccine
In laboratory development	<ul style="list-style-type: none">• Porcine Circovirus vaccine• Porcine Parvovirus vaccine	<ul style="list-style-type: none">• Infectious Laryngotracheitis Virus

Imugene's platform technology

Expanding uses address future needs

Commercial advantages

- **Cost effective to manufacture & administer** via water, feed, aerosol, or injection
- **High efficacy** at an early age
- Deliver only **key genetic information**
- Can deliver **multiple genes**
- **Do not cause disease or create meat residues** so are safe for human consumption
- **Do not genetically modify the host animal**, but work by stimulating the animals own immune system.

Market

- Global market - US\$3 billion + per year
- Biological products ↑
- Antibiotics ↓
- Poultry Productivity Enhancer
 - 48 billion broilers produced each year
- PRRS
 - losses of up to US\$1 billion every year

Looking outward

- **Renewed focus on market engagement**
 - Engagement of Buchan Consulting
 - Perception study
 - Biannual shareholder briefings
 - Regular analyst briefings, focused on expanding support base
 - Refresh of website
 - Media relations

2008 - 2009: A pivotal year

- Technology transferred to Merial
- Swine influenza - completed laboratory construction & testing of vaccines for H1N1 and H3N2 strains
- Expansion of patent portfolio
- Achieved positive operating annual cash flow of AU\$959,000

A blue gradient banner at the top of the slide. On the left, there is a faint image of laboratory glassware (beakers and test tubes) containing green liquid. On the right, there is a faint image of a green chicken.

Imugene Limited

ASX: IMU

Dr Warwick Lamb

Managing Director

+ 61 8 9440 2660

wlamb@imugene.com

Further information www.imugene.com

IMUGENE

LIMITED

The logo consists of the word "IMUGENE" in a bold, blue, sans-serif font. Below it is a horizontal oval graphic with a blue-to-green gradient. Underneath the oval is the word "LIMITED" in a smaller, blue, sans-serif font.